UPDATE: Tigress Initiates Coverage On Illumina
In a report released Friday, Tigress analyst Philip Van Deusen initiated coverage on Illumina (NASDAQ: ILMN) with a Buy rating.
Analysts at Tigress favor Illumina for reducing costs in its genomic health progress with its genetic testing, diagnosis and individualized treatment. Illumina's development of hardware will strengthen, influencing an increase to barriers to entry. Tigress holds high expectations for Illumina sequencing machines, growing 51 percent year over year and making a majority of the company's revenue.
Latest Ratings for ILMN
|May 2015||Morgan Stanley||Upgrades||Equal-weight||Overweight|
|Apr 2015||Tigress Financial||Upgrades||Buy||Strong Buy|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.